Vascular Gene Therapy

NIH awards grant to conduct research for vascular gene delivery

Published in Biotech Business Week, September 27th, 2004

Genetronics Biomedical Corp. (GEB), a late-stage developer of cancer and other therapies using electroporation-enabled delivery of drugs, DNA vaccines, and genes, has been awarded a grant by the National Institutes of Health (NIH) to conduct research in the field of vascular gene therapy.

The $100,000 phase I grant, entitled "Ex vivo venous gene delivery by pulsed electric fields," was awarded through the small business innovative research (SBIR) program and may be followed, upon evaluation, by a phase II award of up to $1 million. Vascular diseases are the number 1 cause of death in the U.S. and other industrialized countries.

Vascular transplants,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Biotech Business Week

Source: Biotech Business Week (2004-09-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry